Gastrointestinal stromal tumours
Gastrointestinal stromal tumours (GIST) have an incidence of~ 1.2 per 105 individuals per
year in most countries. Around 80% of GIST have varying molecular changes, predominantly …
year in most countries. Around 80% of GIST have varying molecular changes, predominantly …
Recent progress of targeted G-quadruplex-preferred ligands toward cancer therapy
A G-quadruplex (G4) is a well-known nucleic acid secondary structure comprising guanine-
rich sequences, and has profound implications for various pharmacological and biological …
rich sequences, and has profound implications for various pharmacological and biological …
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
Background Resistance to approved inhibitors of KIT proto-oncogene, receptor tyrosine
kinase (KIT), and platelet-derived growth factor receptor α (PDGFRA) is a clinical challenge …
kinase (KIT), and platelet-derived growth factor receptor α (PDGFRA) is a clinical challenge …
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial
H Joensuu, M Eriksson, KS Hall, JT Hartmann, D Pink… - Jama, 2012 - jamanetwork.com
Context Adjuvant imatinib administered for 12 months after surgery has improved recurrence-
free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared …
free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared …
[HTML][HTML] Tumour heterogeneity and the evolution of polyclonal drug resistance
RA Burrell, C Swanton - Molecular oncology, 2014 - Elsevier
Cancer drug resistance is a major problem, with the majority of patients with metastatic
disease ultimately developing multidrug resistance and succumbing to their disease. Our …
disease ultimately developing multidrug resistance and succumbing to their disease. Our …
Gastrointestinal stromal tumours: origin and molecular oncology
CL Corless, CM Barnett, MC Heinrich - Nature Reviews Cancer, 2011 - nature.com
Gastrointestinal stromal tumours (GISTs) are a paradigm for the development of
personalized treatment for cancer patients. The nearly simultaneous discovery of a …
personalized treatment for cancer patients. The nearly simultaneous discovery of a …
Molecular chess? Hallmarks of anti-cancer drug resistance
IA Cree, P Charlton - BMC cancer, 2017 - Springer
Background The development of resistance is a problem shared by both classical
chemotherapy and targeted therapy. Patients may respond well at first, but relapse is …
chemotherapy and targeted therapy. Patients may respond well at first, but relapse is …
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
W Pao, J Chmielecki - Nature Reviews Cancer, 2010 - nature.com
Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was
first recognized in 2004 as a distinct, clinically relevant molecular subset of lung cancer. The …
first recognized in 2004 as a distinct, clinically relevant molecular subset of lung cancer. The …
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors
GD Demetri, M Von Mehren, CR Antonescu… - Journal of the National …, 2010 - jnccn.org
Background Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal
tumors of the gastrointestinal tract. Neoplastic GIST cells seem to arise from a common …
tumors of the gastrointestinal tract. Neoplastic GIST cells seem to arise from a common …
Avapritinib versus regorafenib in locally advanced unresectable or metastatic GI stromal tumor: a randomized, open-label phase III study
PURPOSE Primary or secondary mutations in KIT or platelet-derived growth factor receptor
alpha (PDGFRA) underlie tyrosine kinase inhibitor resistance in most GI stromal tumors …
alpha (PDGFRA) underlie tyrosine kinase inhibitor resistance in most GI stromal tumors …